Breaking News Instant updates and real-time market news.

Therapix Biosciences executed a non-exclusive material transfer agreement with Yissum, the technology transfer company of The Hebrew University of Jerusalem, for two synthetic cannabinoids synthesized by the university. Therapix plans to initiate a preclinical study during Q4 to evaluate the opioid-sparing effect of these compounds in a rat model. In view of their parallel actions in pain, cannabinoids and opioids together may allow the development of a novel therapy that could exhibit a synergistic effect that reduces the therapeutic effective dose of opioids

TRPXTherapix Biosciences

$5.08

0.08 (1.60%)

06/05/17

LTCO

06/05/17INITIATIONTarget $18LTCOBuy

Therapix Biosciences initiated with a Buy at Ladenburg

Laidlaw analyst Francois Brisebois initiated Therapix Biosciences with a Buy and an $18 price target saying lead candidate THXTS01, an orally available pill consisting of FDA approved dronabinol and palmitoylethanolamide for the treatment of symptoms related to Tourette Syndrome, has little competition and a large market opportunity.